Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase III Study of Impact of Treatment With Rituximab on the Progression of Humoral Acute Rejection After Renal Transplantation

NCT01350882 is registered in ClinicalTrials.gov with University Hospital, Tours as lead sponsor.

NCT NCT01350882
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01350882 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase III Study of Impact of Treatment With Rituximab on the Progression of Humoral Acute Rejection After Renal Transplantation
Lead sponsor
University Hospital, Tours
Phase
Phase 3
Overall status
Completed
Start date
October 31, 2008
Completion date
October 31, 2013
Enrollment
40 (actual)
Sites
30

Conditions

As the registry lists them; a condition with its own page is linked.

humoral rejection in kidney transplantation